KDMN
Price:
$9.5
Market Cap:
$0
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleosi...[Read more]
Industry
Biotechnology
IPO Date
2016-07-27
Stock Exchange
NYSE
Ticker
KDMN
According to Kadmon Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is -77.31%. This represents a change of -25.12% compared to the average of -103.24% of the last 4 quarters.
The mean historical ROE of Kadmon Holdings, Inc. over the last ten years is -539.66%. The current -77.31% ROE has changed -85.67% with respect to the historical average. Over the past ten years (40 quarters), KDMN's ROE was at its highest in in the September 2016 quarter at 1.33%. The ROE was at its lowest in in the December 2017 quarter at -1034.70%.
Average
-539.66%
Median
-37.03%
Minimum
-4537.77%
Maximum
828.66%
Discovering the peaks and valleys of Kadmon Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.09%
Maximum Annual ROE = 828.66%
Minimum Annual Increase = -647.61%
Minimum Annual ROE = -4537.77%
Year | ROE | Change |
---|---|---|
2020 | -93.87% | 153.52% |
2019 | -37.03% | -39.66% |
2018 | -61.36% | -98.65% |
2017 | -4537.77% | -647.61% |
2016 | 828.66% | 1.09% |
2015 | 69.36% | 27.57% |
The current ROE of Kadmon Holdings, Inc. (KDMN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-64.09%
5-year avg
-780.28%
10-year avg
-539.66%
Kadmon Holdings, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kadmon Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kadmon Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kadmon Holdings, Inc.'s ROE?
How is the ROE calculated for Kadmon Holdings, Inc. (KDMN)?
What is the highest ROE for Kadmon Holdings, Inc. (KDMN)?
What is the 3-year average ROE for Kadmon Holdings, Inc. (KDMN)?
What is the 5-year average ROE for Kadmon Holdings, Inc. (KDMN)?
How does the current ROE for Kadmon Holdings, Inc. (KDMN) compare to its historical average?